Deutsche Bank Upgrades Acadia Healthcare (ACHC) to Buy, Boosts Target to $19
Tweet Send to a FriendGet Alerts ACHC Hot Sheet
Price: $32.49 -0.76%
Rating Summary:
8 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 13
Rating Summary:
8 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 16 | New: 13
Trade ACHC Now!
Deutsche Bank upgraded Acadia Healthcare (NASDAQ: ACHC) from Hold to Buy. The price target was raised from $15 to $19.
The firm said, "With the recent equity offering, the balance sheet and capacity to accretively acquire put it in a place where the next meaningful N-T move in the shares is likely to be up and not down, in our view. Given the growth outlook and improved capital structure, we believe a higher multiple is warranted (we go from 8.5x to 9.5x 2013E EV/EBITDA or 20x P/E)..."
Deutsche Bank continues to like: "(1) attractive organic growth in the behavioral segment; (2) reasonably good consolidation opportunities, including mid-sized chains that could “move the needle”; and (3) solid FCF and ROIC characteristics given the margin profile (low/mid-20% EBITDA margins) and low capex requirements (2%-3% of rev)."
For an analyst ratings summary and ratings history on Acadia Healthcare click here. For more ratings news on Acadia Healthcare click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm said, "With the recent equity offering, the balance sheet and capacity to accretively acquire put it in a place where the next meaningful N-T move in the shares is likely to be up and not down, in our view. Given the growth outlook and improved capital structure, we believe a higher multiple is warranted (we go from 8.5x to 9.5x 2013E EV/EBITDA or 20x P/E)..."
Deutsche Bank continues to like: "(1) attractive organic growth in the behavioral segment; (2) reasonably good consolidation opportunities, including mid-sized chains that could “move the needle”; and (3) solid FCF and ROIC characteristics given the margin profile (low/mid-20% EBITDA margins) and low capex requirements (2%-3% of rev)."
For an analyst ratings summary and ratings history on Acadia Healthcare click here. For more ratings news on Acadia Healthcare click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- Janney Capital Boosts PT on Gap (GPS) Post Q1
- Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
Create E-mail Alert Related Categories
UpgradesRelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
